We herewith submit unaudited financial results for the quarter and half year ended on 30th September, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Link Pharma Chem reported Q2 FY26 revenue from operations of Rs 629.32 lakhs, up about 31% from Rs 479.82 lakhs in Q2 FY25. For H1 FY26, revenue was Rs 1,410.80 lakhs vs Rs 1,364.45 lakhs in H1 FY25, a modest ~3.4% rise. The company swung back to profit, posting a Q2 PAT of Rs 1.56 lakhs against a loss of Rs 30.63 lakhs last year, and an H1 PAT of Rs 17.73 lakhs against a marginal loss of Rs 0.99 lakhs earlier. Auditor CNK & Associates LLP issued an unmodified limited review report with no qualifications. The Board also accepted the resignation of Company Secretary Ms. Khushbu Prakashbhai Patel, effective 16 December 2025.
A return to profitability and strong Q2 revenue growth are positive signals for shareholders, though the small absolute profit and only marginal H1 revenue uptick limit the upside. The departure of the Compliance Officer ahead of year-end filings is a minor governance item to watch, but no red flags in the auditor's report.